Patient selection and classification for atrial fibrillation ablation: Thinking beyond duration

Heart Rhythm

Volumn 6, Issue 10, 2009, Pages 1522-1525

  Singh, Jagmeet P ^a   Morady, Fred ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Atrial fibrillation; Catheter ablation; Pulmonary vein isolation

Indexed keywords

ANTIARRHYTHMIC AGENT;

ARTICLE; ATRIAL FIBROSIS; CATHETER ABLATION; DISEASE CLASSIFICATION; DRUG USE; FIBROSIS; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HUMAN; LONG STANDING PERSISTENT ATRIAL FIBRILLATION; PAROXYSMAL HEART ATRIUM FIBRILLATION; PATIENT SELECTION; PERSISTENT ATRIAL FIBRILLATION; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; CLASSIFICATION; METHODOLOGY; PATHOLOGY;

ATRIAL FIBRILLATION; CATHETER ABLATION; FIBROSIS; HUMANS; PATIENT SELECTION;

EID: 77949519880     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.04.003     Document Type: Article

References (40)

1. Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 48 (2006) 2340-2347
2. Oral H., Pappone C., Chugh A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 354 (2006) 934-941
3. Jais P., Cauchemez B., Macle L., et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118 (2008) 2498-2505
4. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293 (2005) 2634-2640
5. Lemola K., Oral H., Chugh A., et al. Pulmonary vein isolation as an end point for left atrial circumferential ablation of atrial fibrillation. J Am Coll Cardiol 46 (2005) 1060-1066
6. Arruda M., and Natale A. Ablation of permanent AF: adjunctive strategies to pulmonary veins isolation: targeting AF NEST in sinus rhythm and CFAE in AF. J Interv Card Electrophysiol 23 (2008) 51-57
7. Willems S., Klemm H., Rostock T., et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J 27 (2006) 2871-2878
8. Oral H., Scharf C., Chugh A., et al. Catheter ablation for paroxysmal atrial fibrillation: segmental pulmonary vein ostial ablation versus left atrial ablation. Circulation 108 (2003) 2355-2360
9. Zou R., Kneller J., Leon L.J., and Nattel S. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am J Physiol Heart Circ Physiol 289 (2005) H1002-H1012
10. Hou Y., Scherlag B.J., Lin J., et al. Ganglionated plexi modulate extrinsic cardiac autonomic nerve input: effects on sinus rate, atrioventricular conduction, refractoriness, and inducibility of atrial fibrillation. J Am Coll Cardiol 50 (2007) 61-68
11. Calkins H., Brugada J., Packer D.L., et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4 (2007) 816-861
12. Frustaci A., Chimenti C., Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
13. Kilicaslan F., Verma A., Saad E., et al. Efficacy of catheter ablation of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy. Heart Rhythm 3 (2006) 275-280
14. Khan M.N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359 (2008) 1778-1785
15. Boldt A., Wetzel U., Lauschke J., et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90 (2004) 400-405
16. Bauer A., McDonald A.D., and Donahue J.K. Pathophysiological findings in a model of persistent atrial fibrillation and severe congestive heart failure. Cardiovasc Res 61 (2004) 764-770
17. Schoonderwoerd B.A., Van Gelder I.C., Van Veldhuisen D.J., et al. Electrical and structural remodeling: role in the genesis and maintenance of atrial fibrillation. Prog Cardiovasc Dis 48 (2005) 153-168
18. Cha T.J., Ehrlich J.R., Zhang L., et al. Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure. Circulation 110 (2004) 1520-1526
19. Everett IV T.H., Li H., Mangrum J.M., et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 102 (2000) 1454-1460
20. Li D., Fareh S., Leung T.K., et al. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 100 (1999) 87-95
21. Moe G.K., Rheinboldt W.C., and Abildskov J.A. A computer model of atrial fibrillation. Am Heart J 67 (1964) 200-220
22. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339 (1998) 659-666
23. Jalife J., Berenfeld O., Skanes A., et al. Mechanisms of atrial fibrillation: mother rotors or multiple daughter wavelets, or both?. J Cardiovasc Electrophysiol 9 (1998) S2-S12
24. Skanes A.C., Mandapati R., Berenfeld O., et al. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. Circulation 98 (1998) 1236-1248
25. Everett T.H., and Olgin J.E. Atrial fibrosis and the mechanisms of atrial fibrillation. Heart Rhythm 4 (2007) S24-S27
26. Gerstenfeld E.P., Callans D.J., Dixit S., et al. Incidence and location of focal atrial fibrillation triggers in patients undergoing repeat pulmonary vein isolation: implications for ablation strategies. J Cardiovasc Electrophysiol 14 (2003) 685-690
27. Sauer W.H., McKernan M.L., Lin D., et al. Clinical predictors and outcomes associated with acute return of pulmonary vein conduction during pulmonary vein isolation for treatment of atrial fibrillation. Heart Rhythm 3 (2006) 1024-1028
28. Akar J.G., Everett IV T.H., Kok L.C., et al. Effect of electrical and structural remodeling on spatiotemporal organization in acute and persistent atrial fibrillation. J Cardiovasc Electrophysiol 13 (2002) 1027-1034
29. Knackstedt C., Gramley F., Schimpf T., et al. Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. Cardiovasc Pathol 17 (2008) 318-324
30. Avitall B., Bi J., Mykytsey A., et al. Atrial and ventricular fibrosis induced by atrial fibrillation: evidence to support early rhythm control. Heart Rhythm 5 (2008) 839-845
31. Hof I., Arbab-Zadeh A., Scherr D., et al. Correlation of left atrial diameter by echocardiography and left atrial volume by computed tomography. J Cardiovasc Electrophysiol 20 (2009) 159-163
32. Kostin S., Klein G., Szalay Z., et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54 (2002) 361-379
33. Letsas K.P., Weber R., Burkle G., et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace 11 (2009) 158-163
34. Lin C.S., and Pan C.H. Regulatory mechanisms of atrial fibrotic remodeling in atrial fibrillation. Cell Mol Life Sci 65 (2008) 1489-1508
35. Ehrlich J.R., Hohnloser S.H., and Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27 (2006) 512-518
36. Al Chekakie M.O., Akar J.G., Wang F., et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 18 (2007) 942-946
37. Guerra J.M., Everett IV T.H., Lee K.W., et al. Effects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation 114 (2006) 110-118
38. Maes A., Flameng W., Borgers M., et al. Regional myocardial blood flow, glucose utilization and contractile function before and after revascularization and ultrastructural findings in patients with chronic coronary artery disease. Eur J Nucl Med 22 (1995) 1299-1305
39. Raman S.V., Ng V.Y., Neff M.A., et al. Volumetric cine CMR to quantify atrial structure and function in patients with atrial dysrhythmias. J Cardiovasc Magn Reson 7 (2005) 539-543
40. Rodrigues A.C., Scannavacca M.I., Caldas M.A., et al. Left atrial function after ablation for paroxysmal atrial fibrillation. Am J Cardiol 103 (2009) 395-398